Search
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalit in collaboration with Eli Lilly and Company. … [L15316, L15321] Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk
Nedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalNedaplatin is a second generation platinum analog [A20300]. It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.
Synonyms: (glycolato-O,O')diammineplatinum(II), cis-Diammine(glycolato)platinum(II)Rivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalHowever there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. … Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary.
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalzone lymphoma in selected patients. … [L16028] Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure
Formaldehyde
go.drugbank.com/drugs/DB03843ApprovedVet approvedIn solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. … Formaldehyde solution (formalin) is considered a hazardous compound, and its vapor toxic. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717)
Categories: Compounds used in a research, industrial, or household settingCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.
Gepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.
Categories: Triazaacenaphthylene Bacterial Type II Topoisomerase InhibitorDiphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalThis medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. … A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine.
Kaolin
go.drugbank.com/drugs/DB01575ApprovedKaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. … Kaolin is a layered silicate mineral.
Mixtures: Pranicura IILasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … suitable for use in patients with pre-existing cardiovascular disorders.